{"id":"mm120-lsd-d-tartrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Perceptual disturbances / hallucinations"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Elevated blood pressure"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Mydriasis (pupil dilation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LSD binds to and activates serotonin receptors throughout the brain, with particular affinity for 5-HT2A receptors in cortical regions. This activation is thought to promote neuroplasticity and alter default mode network activity, potentially facilitating therapeutic psychological insights and emotional processing. The D-tartrate salt formulation improves stability and bioavailability for clinical use.","oneSentence":"MM120 is a formulated version of LSD (lysergic acid diethylamide) that acts as a serotonin 5-HT receptor agonist, particularly at 5-HT1A and 5-HT2A receptors, to modulate neural circuits involved in mood and perception.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:56.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder (in development)"}]},"trialDetails":[{"nctId":"NCT06941844","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2025-04-14","conditions":"Major Depressive Disorder","enrollment":149},{"nctId":"NCT06809595","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)","status":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2025-01-29","conditions":"Generalized Anxiety Disorder","enrollment":250},{"nctId":"NCT06741228","phase":"PHASE3","title":"A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)","status":"RECRUITING","sponsor":"Definium Therapeutics US, Inc.","startDate":"2024-12-11","conditions":"Generalized Anxiety Disorder","enrollment":200},{"nctId":"NCT05407064","phase":"PHASE2","title":"A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms","status":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","startDate":"2022-08-24","conditions":"Anxiety Generalized","enrollment":198},{"nctId":"NCT05200936","phase":"PHASE2","title":"Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial","status":"COMPLETED","sponsor":"Definium Therapeutics US, Inc.","startDate":"2021-12-17","conditions":"ADHD, Attention Deficit Disorder","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MM120 (LSD D-Tartrate)","genericName":"MM120 (LSD D-Tartrate)","companyName":"Definium Therapeutics US, Inc.","companyId":"definium-therapeutics-us-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MM120 is a formulated version of LSD (lysergic acid diethylamide) that acts as a serotonin 5-HT receptor agonist, particularly at 5-HT1A and 5-HT2A receptors, to modulate neural circuits involved in mood and perception. Used for Major depressive disorder (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}